A2b93dff E83a 4115 A9fa 03a3be46e05f

2017-01-30

: Pdf A2B93Dff-E83A-4115-A9Fa-03A3Be46E05F a2b93dff-e83a-4115-a9fa-03a3be46e05f 1 2017 pdf

Open the PDF directly: View PDF PDF.
Page Count: 30

DownloadA2b93dff-e83a-4115-a9fa-03a3be46e05f
Open PDF In BrowserView PDF
1/30/2017

Vumedi January 2017

Challenging Case
Paul Sorajja, MD
Director, Center for Valve and Structural Heart Disease
Minneapolis Heart Institute
Abbott Northwestern Hospital
Disclosures: none

84 year old woman
MV repair in 2005
New DOE for 6 months
NYHA III
Frail

1

1/30/2017

What next?

2

1/30/2017

3

1/30/2017

4

1/30/2017

TAVR in bicuspid Aortic
valve

Itsik Ben-Dor ,MD
Augusto Pichard ,MD
Medstar Washington Hospital Center.
Washington, DC

Classification of Bicuspid Valves
7%

88%

5%

71%

15%

3%

Sievers et at. J Thorac Cardiovasc Surg 2007;133:1226-33.

Potential Problems in Bicuspids
 Often heavily calcified






Incomplete valve expansion
Paravalvar leak
Annulus rupture
Coronary obstruction
Higer rate of pacemaker

 Frequently associated with
ascending aortic aneurysm
 Risk of rupture/dissection

 Oval shaped valve area

 Risk of paravalvar leak
 Sizing is difficult
 Long-term durability of the TAVI valve?

 For these reasons bicuspid valves had been
excluded from all randomized trials

1

1/30/2017

Valve size in bicuspid valves
 Avoid oversizing
 Risk of rupture
 Larger self-expanding valves have less radial force

 Usually it is safe to undersize
 Very large annuli may still be
suitable for TAVI due to higher
degree of calcification

Sizing
Balloon sizing

29 mm Core Valve

Case History
• 81 year-old woman with presents with progressive SOB and
leg edema
•
 PMH:
• Atrial fibrillation s/p retinal embolus on Eliqius
•

DVT

Echo :

EF 20-25%

STS score: 2.4%

AVA 0.5cm2 v2 6.3m/sec, mean gradient 106mmHg
Mild to moderate AR

BAV (2 months before) – Maxi 22mm AVA 0.25 to 0.52 cm2
Mean gradient 100 to 43mmHg

2

1/30/2017

Echo
Date of ECHO 01.27.2016 (post BAV)
LVEF ( 20%) * 45%

Aortic Valve Area (< 1.0cm2)* 0.7

Mean Aortic Gradient (
44
40mmHg)*

Aortic Valve Area Index (<
0.41
0.6cm2/m2)*
Normal size,
RV Size and Function borderline reduced
systolic function

Peak Velocity ( 4.0 m/sec)* 4.2
Estimated Systolic
36
Pulmonary Pressure (mmHg)
Other Valvular Findings Mild MR, trace AR; mild TR
Native Coronary and Graft
Findings

LM 30%; LAD 10%; LCX = 10%; RCA=10%

Bicuspid valve

Which Valve would you choose ?

1.Balloon expandable
2. Self expandable

3

1/30/2017

4

1/30/2017

CT Analysis

Annulus by CT

Measure

Short Annulus Diameter

25.1 mm

Long Annulus Diameter

30.0 mm

Annular Perimeter

85.3 mm

Annular Area

581.1 mm2

Derived diameter (perimeter/area)

27.2/27.2 mm/mm

CT Analysis

Aortic Root by CT

Measure

Sinus of Valsalva Diameter

37.7(L)x30.5(R)x33.2(N)mm

STJ Diameter

32.5x35.4mm

Sinus Height

24.1(L)x21.5(R)x24.0(N)mm

Left Coronary Height

13.2mm

Right Coronary Height

15.7mm

Aorta

39.1x40.3mm

Angle

44°

Access

CIA
EIA
CFA

Right

Left

8.7
6.6
6.8

10.4
7.5
7.1

5

1/30/2017

Procedure
• Right femoral two perclose
• Temporary pacer

BAV

Maxi 20/4

Procedure

31 mm core valve

Procedure

6

1/30/2017

Procedure

True balloon 22mm

Echo post valve

Mild to moderate AR

Hospital course
• LBBB – EP study –CAVB with infra-his
conduction block
• Pacemaker day 3
• Echo at 2 days: moderate AR

• Home

day 5

7

1/30/2017

Post discharge
• Shortness of breath with minimal activity
•

TTE and TEE

TEE one month post

Echo Variable (TTE) Measure
Peak Velocity

2.2 m/se

Mean Gradient

11 mmH
g

c

Calculated AVA

Severity of AR
Severity of MR
Ejection Fraction

n/a cm2

Severe
Mild
55-60 %

2 paravalvular leaks: the larger leak in the
non-coronary cusp and the smaller is
more anterior.
Reversal of flow in the descending and
abdominal aorta consistent with severe
paravalvular leak.

Next step ?
• Para valvular closure device
• Valve in valve core or Edwards
• Surgery

8

1/30/2017

S3

Annulus by CT

Measure

Short Annulus Diameter
Long Annulus Diameter
Annular Perimeter
Annular Area
Oversizing

25.1 mm
30.0 mm
85.3 mm
581.1 mm2
11.9 %

Procedure

29mm S3 Edwards

Procedure

9

1/30/2017

Procedure

No AR

Hospital course
Day one post procedure mild chest pain

Cardiac enzyme – troponin 14 → 35 → 43 stable

Hospital course
Day one post procedure mild chest pain

10

1/30/2017

Hospital course
Discussion with CV surgery for CABG or PCI
More than 24 hours post infarct
Medical treatment
Discharge day 5 after the procedure

11

1/30/2017

Challenges for TAVI in BAV
Asymmetric anatomy
Annulus-orifice “mismatch”

Incorrect valve
sizing

Incomplete apposition

Non-circular &
inadequate
expansion

Migration

Paravalvular leak
Aggressive
post-dilation

Impaired
valve
durability

Annular rupture

Valve-in-valve

Conclusions
 TAVI in bicuspid valves is feasible but may be
technically more difficult.
 Results are comparable to those tricuspid valves.
 Paravalvular leaks may be more frequent.
 Pacemaker may be more frequent.
 Oversizing of the valve should be avoided.
 Balloon sizing may be better than CT sizing.
Supra-annular sizing better than balloon sizing.
 Patients with large annulus may still be suitable
for TAVI if the valve is bicuspid
 Better results can be expected with newer
valves.

CT Analysis (1/6/2017)
S3

Annulus by CT

Measure

Short Annulus Diameter

24.0 mm

Long Annulus Diameter

31.0 mm

Annular Perimeter
Annular Area
Oversizing

89.0 mm
621.0 mm2

3%

12

1/30/2017

CT Analysis (1/6/2017)

Aortic Root by CT

Measure

Sinus of Valsalva Diameter

(L)35x(R)32x(N)37mm

Sinotubular Junction Diameter

31x32mm

Sinus Height

(L)21x(R)20x(N)25mm

Left Coronary Height

19mm

Right Coronary Height

15mm

Aorta

35x37mm

Angle

53°

13

1/30/2017

14

1/30/2017

Preemptive Alcohol Septal
Ablation in Prevention of
LVOT Obstruction for TMVR
Christopher U. Meduri, MD MPH
Co-Director Marcus Heart Valve Center
Piedmont Heart Institute
Atlanta, GA

Disclosures
Affiliation
Company
● Proctor/Speaker/Advisory Board
● Boston Scientific
● Proctor/Speaker/Consultant/Grant ●Medtronic
● Proctor/Grant
● Edwards
• Proctor/Consultant
● Mitralign

Will be discussing the use of THV for off-label uses

Page 2

M.K.
• 76 y/o woman with severe PVD, LM disease, severe
AS and severe MS with MAC with NYHA III
symptoms

Page 3

1

1/30/2017

M.K.
• 76 y/o woman with severe PVD, LMT disease,
severe AS and severe MS with MAC with NYHA III
symptoms
• Extreme risk because of porcelain aorta

Page 4

Baseline Angio

Page 5

Coronary Stenting

Page 6

2

1/30/2017

TAVR Planning
• Normal LV/RV
function
• Aortic velocity = 4.1
meters/sec
• Aortic annulus area
= 309 mm2
• Area derived
annulus = 19.8 mm
• Ileofemorals = 4.0 –
4.5 cm
Page 7

Do We Treat Mitral Stenosis?

Aorto-Mitral
Angle 106
degrees
Septal Bulge
1.8cm

Page 8

23 mm Sapien XT

Page 9

3

1/30/2017

23 mm Sapien XT

Page 10

23 mm Sapien XT

Page 11

Recurrent Dyspnea 6 months later
• 23 Sapien XT gradients = 27/15 mmHg (post
procedure = 28/17 mmHg)
• No aortic regurgitation

Page 12

4

1/30/2017

Re-assessment of Mitral Valve

Page 13

Re-assessment of Mitral Valve

Page 14

Re-assessment of Mitral Valve

Page 15

5

1/30/2017

Severe MAC

Page 16

Risk Factors for LVOT Obstruction

Page 17

Severely Hypertrophied Basal Septum

Page 18

6

1/30/2017

Aorto-Mitral Images

Page 19

Proceed?
• Very high risk of LVOT obstruction
• No potential surgical bailout for patient if worse
• Must be confident in result and have ability to
remove if needed

• Plan for septal ablation and request compassionate
use Lotus in MAC from FDA

Page 20

Alcohol Septal Ablation

LVOT Pre-Ablation

LVOT Post-Ablation

Page 21

7

1/30/2017

Page 22

Pre Procedure

Page 23

Page 24

8

1/30/2017

Page 25

TEE Guidance of Implant Depth

Page 26

Page 27

9

1/30/2017

Page 28

No LVOT Gradient

Page 29

Post Procedure

Page 30

10

1/30/2017

No MR/PVL

Page 31

Page 32

Post-Procedure
• Extubated on table
• Within 6 hours walking laps around CVICU saying, “I
feel like a new person”
• Discharge POD 2
• Walked 2.5 miles without stopping within 1 week of
procedure!

Page 33

11

1/30/2017

30 Day Follow-Up CT

Page 34

Thank You

Christopher.Meduri@piedmont.org

Page 35

12



Source Exif Data:
File Type                       : PDF
File Type Extension             : pdf
MIME Type                       : application/pdf
PDF Version                     : 1.4
Linearized                      : No
Modify Date                     : 2017:01:30 17:32:59-05:00
Creator                         : PDFMerge! (http://www.pdfmerge.com)
Create Date                     : 2017:01:30 17:32:59-05:00
Producer                        : iText® 5.5.8 ©2000-2015 iText Group NV (ONLINE PDF SERVICES; licensed version)
Page Count                      : 30
EXIF Metadata provided by EXIF.tools

Navigation menu